Epigral Limited reported its highest-ever quarterly revenue of ₹736 crore for Q4 FY26, representing a 17% growth year-on-year. Driven by strong demand and operational efficiencies, the company saw its EBITDA margin rise to 23%. Following this performance, the Board has proposed a final dividend of ₹5 per equity share. The company continues to advance its strategic capex projects in CPVC and Epichlorohydrin to meet growing domestic demand.
Financial Performance Review
Epigral Limited demonstrated strong growth momentum in the quarter ended March 31, 2026. The company achieved a record revenue of ₹736 crore, marking a 22% sequential growth compared to the previous quarter. Profit After Tax (PAT) experienced a significant jump of 109% sequentially, reaching ₹82 crore. This recovery was underpinned by higher plant utilization rates, which climbed above 80%, and stabilized raw material costs.
Operational and Strategic Highlights
During FY2026, the company invested ₹394 crore in capital expenditure projects, which are progressing as per schedule. Key capacity expansion updates include:
- CPVC Resin: Targeted capacity increase to 1,50,000 TPA.
- Epichlorohydrin: Targeted capacity increase to 1,00,000 TPA.
- Renewable Energy: Expansion of the Wind Solar Hybrid Power Plant to 38.14 MW.
Business Outlook
The company’s focus on specialty chemicals remains a core growth driver, with the revenue contribution from the Derivatives & Specialty business increasing to 54% in Q4 FY26. Despite a challenging first half of the fiscal year due to weather impacts and planned maintenance, the robust recovery observed since November indicates a positive outlook for FY2027. Management remains committed to delivering long-term stakeholder value through further product integration and the successful commissioning of ongoing infrastructure projects.
Source: BSE
